WO2008042190A3 - Détection de maladies neurodégénératives - Google Patents

Détection de maladies neurodégénératives Download PDF

Info

Publication number
WO2008042190A3
WO2008042190A3 PCT/US2007/020795 US2007020795W WO2008042190A3 WO 2008042190 A3 WO2008042190 A3 WO 2008042190A3 US 2007020795 W US2007020795 W US 2007020795W WO 2008042190 A3 WO2008042190 A3 WO 2008042190A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disease
detection
subject
methods
tdp
Prior art date
Application number
PCT/US2007/020795
Other languages
English (en)
Other versions
WO2008042190A2 (fr
Inventor
Virginia M Y Lee
John Q Trojanowski
Original Assignee
Univ Pennsylvania
Virginia M Y Lee
John Q Trojanowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Virginia M Y Lee, John Q Trojanowski filed Critical Univ Pennsylvania
Publication of WO2008042190A2 publication Critical patent/WO2008042190A2/fr
Publication of WO2008042190A3 publication Critical patent/WO2008042190A3/fr
Priority to US12/412,015 priority Critical patent/US8354236B2/en
Priority to US13/712,085 priority patent/US20130184441A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés d'évaluation de l'absence ou de la présence d'une maladie neurodégénérative chez un sujet, ce procédé consistant à caractériser TDP-43 dans un échantillon de tissu prélevé chez le sujet. L'invention concerne également des méthodes de diagnostic d'une maladie neurodégénérative chez un sujet, ainsi que des méthodes visant à déterminer l'efficacité d'un médicament pour lutter contre une maladie neurodégénérative. L'invention concerne également de nouveaux anticorps qui se lient à TDP-43.
PCT/US2007/020795 2006-09-29 2007-09-26 Détection de maladies neurodégénératives WO2008042190A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/412,015 US8354236B2 (en) 2006-09-29 2009-03-26 Detection of neurodegenerative disease
US13/712,085 US20130184441A1 (en) 2007-09-26 2012-12-12 Detection of Neurodegenerative Disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84831806P 2006-09-29 2006-09-29
US60/848,318 2006-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/412,015 Continuation-In-Part US8354236B2 (en) 2006-09-29 2009-03-26 Detection of neurodegenerative disease

Publications (2)

Publication Number Publication Date
WO2008042190A2 WO2008042190A2 (fr) 2008-04-10
WO2008042190A3 true WO2008042190A3 (fr) 2008-08-07

Family

ID=39268966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/020795 WO2008042190A2 (fr) 2006-09-29 2007-09-26 Détection de maladies neurodégénératives

Country Status (1)

Country Link
WO (1) WO2008042190A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354236B2 (en) 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
EP2723866B1 (fr) 2011-06-22 2018-03-28 Universite Laval Procédés de pronostic et/ou de diagnostic d'une maladie neurodégénérative, procédés d'identification de composés candidats et composés pour le traitement d'une maladie neurodégénérative
ITRM20110582A1 (it) 2011-11-05 2013-05-06 Biotechnology Icgeb Modello cellulare per la selezione di molecole che influenzano l aggregazione di tdp-43
CA2874083C (fr) 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
WO2017079161A2 (fr) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Traitement d'une maladie neurodégénérative avec du chlorite de sodium
WO2023194565A1 (fr) 2022-04-08 2023-10-12 Ac Immune Sa Molécules de liaison anti-tdp-43

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUMANN, SCIENCE, vol. 314, 2006, pages 130 - 133 *

Also Published As

Publication number Publication date
WO2008042190A2 (fr) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2012054639A3 (fr) Systèmes de rmn et procédés de détection rapide d'analytes
IL191712A0 (en) Neurodegenerative disease detection method, detecting program, and detector
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2012054588A3 (fr) Dispositifs à conduits et procédés de détection et de traitement d'analytes
WO2006124526A3 (fr) Procede d'attribution d'efficacite d'un regime de traitement
WO2008060394A3 (fr) Procédés et essais pour détecter des auto-anticorps spécifiques au gp73
WO2006090389A3 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
TWI312864B (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
WO2006088823A3 (fr) Procede de detection de proteines et de prions a repliement incorrect
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2009111033A3 (fr) Détection de biomarqueurs et complexes de biomarqueurs
EP2535718A3 (fr) Procédé de diagnostic précoce de maladie rénale
NL1033076A1 (nl) Een beeldvormingskatheter en werkwijze voor volumetrische ultrageluidsbeeldvorming.
EP1877795A4 (fr) Profilage diagnostique d'anticorps seriques
WO2008042190A3 (fr) Détection de maladies neurodégénératives
WO2008008708A3 (fr) Test de diagnostic du cancer du poumon
WO2008033427A3 (fr) Compositions et procédés de détection d'une maladie lysosomale
WO2008054764A3 (fr) Biomarqueurs pour cancer colorectal
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
WO2010009171A3 (fr) Activation de src pour déterminer le pronostic du cancer et en tant que cible pour la thérapie du cancer
WO2008131261A3 (fr) Biomarqueurs peptidiques de maladie cardiovasculaire
WO2007106466A3 (fr) Bêta-2 microglobuline utilisée comme biomarqueur pour des maladies artérielles périphériques
PL376121A1 (pl) Zestaw diagnostyczny do badania surowic zwierząt na obecność przeciwciał RHD oraz zestaw diagnostyczny do wykrywania wirusa RHD
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection
EP1917532A4 (fr) Anticorps monoclonal anti-d-dimère utilisé comme agent de diagnostic pour détecter un d-dimère, une fibrine réticulée et ses dérivés renfermant les d-dimères

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838898

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838898

Country of ref document: EP

Kind code of ref document: A2